CHEN JIN-LONG 4
4 · NGM BIOPHARMACEUTICALS INC · Filed Jan 18, 2023
Insider Transaction Report
Form 4
CHEN JIN-LONG
DirectorChief Scientific Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2023-01-17−85,082→ 0 totalExercise: $1.44Exp: 2023-01-23→ Common Stock (85,082 underlying) - Exercise/Conversion
Common Stock
2023-01-17$1.44/sh+85,082$122,518→ 993,975 total - Sale
Common Stock
2023-01-17$5.15/sh−85,082$438,308→ 908,893 total
Footnotes (3)
- [F1]The exercise occurred because the option was expiring, and shares were sold to pay the exercise price and related tax obligations.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $5.015 to $5.30. The reporting person has provided to the issuer, and undertakes to provide to the staff of the Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Fully vested.